AllegroGraph v9 is here — and it introduces GraphTalker, a major advancement in how people and AI agents interact with enterprise Knowledge Graphs. GraphTalker brings natural-language intelligence directly to the #semanticlayer. https://t.co/gn6Ubu8elT #KnowledgeGraphs#NSAI
Beyond AI: The Critical Role of Biology in Personalized Cancer Therapy
There is widespread hype around using AI to predict patient outcomes in cancer care.
Read the full blog to learn how Cellworks is moving beyond the AI black box: https://t.co/WdOqf3EJvI
#PersonalizedOncology
We were thrilled that Deepak Lala, Cellworks Head of Personalized Medicine, was asked to speak at the Project Management Practitioners Conference 2024 (PMPC-2024), where he introduced Cellworks and our groundbreaking advancements in Computational Personalized Medicine #Cellworks
@HateshirtShop@AndyWest_tweets@jk_rowling So you’d prefer to live in a place where women are not only slaves but also erased from public life? What kind of human are you?
Check out our latest blog by Cellworks Chief Scientific Officer, Dr. Ansu Kumar, exploring whether IDH mutations can predict venetoclax response in AML patients.
Read more here: https://t.co/eAnsiXaVNE
#AML#Biosimulation#PrecisionMedicine#IDHMutations#Cellworks
Results from our new study unveiled at #ESMO24, showed how we identified homologous recombination deficiency(HRD) beyond BRCA mutation status, providing more comprehensive predictions of patient response to PARPi therapies.
Read details here -
https://t.co/deEZnautY4
#Cellworks
Our study presented by Dr.Klein at @IASLC 2024 World Conference on Lung Cancer showcases how the Cellworks biosimulation platform accurately predicts which NSCLC patients will benefit most from combining chemotherapy with immunotherapy.
Read announcement-
https://t.co/rFAsAPmcAl
Read the article published by Precision Medicine Online : Cellworks Aims to Validate Clinical Decision Support Capabilities of Computational Model. We thank Avera Cancer Institute, especially Tobias Meissner, for partnering with us in the myCare-101 study.
https://t.co/L5WTezoxz1
Read the Cellworks Personalized Therapy Biosimulation study presented @IASLC 2024 World Conference on Lung Cancer in San Diego that predicted chemotherapy benefit in osimertinib-treated NSCLC patients with EGFR mutations - https://t.co/IvUhWL0TL5
#WCLC24#Cellworks